Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.10.0.1
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2018
Revenue Recognition [Abstract]  
Revenue Recognition

Revenue by Service Line

 

  Three Months Ended September 30,
  2018   2017
Products:          
Disposable products:          
Functional neurology $ 1,448,850   $ 1,284,029
Biologics and drug delivery   190,993     136,833
Capital equipment   99,961     207,573
Total product revenue   1,739,804     1,628,435
Services:          
Capital equipment and other   62,238     88,635
Biologics and drug delivery   5,000     -
Total service revenue   67,238     88,635
Total revenue $ 1,807,042   $ 1,717,070

  

  Nine Months Ended September 30,
  2018   2017
Products:          
Disposable products:          
Functional neurology $ 3,787,712   $ 4,229,192
Biologics and drug delivery   483,251     291,023
Capital equipment   420,039     923,072
Total product revenue   4,691,002     5,443,287
Services:          
Capital equipment and other   218,742     256,860
Biologics and drug delivery   167,000     -
Total service revenue   385,742     256,860
Total revenue $ 5,076,744   $ 5,700,147